A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma

Status:
RECRUITING

Trial end date:
2026-10-02

Target enrollment:

Participant gender:

The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.

PHASE2

Amgen